Sonoma Pharmaceuticals Receives FDA 510(k) Clearance For Its Microdacyn Wound Irrigation Solution

Sonoma Pharmaceuticals shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

Sonoma Pharmaceuticals Q1 EPS $(0.09) Up From $(0.76) YoY, Sales $6.406M Up From $4.015M YoY

Sonoma Pharmaceuticals (NASDAQ:SNOA) reported quarterly losses of $(0.09) per share. This is a 88.16 percent increase over losses of $(0.76) per share from the same period last year. The company reported $6.406 million

Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue

Sonoma Pharmaceuticals reported record Q1 revenue, narrow loss, doubled U.S. sales and achieved positive adjusted EBITDA for the first time.